Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow-up of a randomized controlled trial

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Feb. 15, 2024

Abstract In our previous randomized controlled trial, we documented significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long Coronavirus disease 2019 (COVID) patients who underwent hyperbaric oxygen therapy (HBOT). The primary objective of the present study was to evaluate enduring 1 year term effects HBOT on COVID syndrome. This longitudinal long-term follow-up included 31 with reported post COVID-19 cognitive symptoms, 40 daily sessions HBOT. Participants were recruited more than one (486 ± 73) after completion last session. Quality life, assessed using short form-36 (SF-36) questionnaire revealed, that results exhibited a similar magnitude improvement as short-term outcomes following across most domains. Regarding sleep quality, observed global score five domains effect sizes moderate during evaluation, these persisted assessment (effect size (ES1) = 0.47–0.79). realm neuropsychiatric evaluated by brief symptom inventory-18 (BSI-18), demonstrated large size, this at evaluation. Both severity (ES1 0.69) interference 0.83), had HBOT, which term. indicate can improve quality psychiatric suffering from COVID. clinical gained are persistent even

Language: Английский

---

Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(11), P. 6151 - 6151

Published: June 7, 2021

The SARS-CoV-2 infection determines the COVID-19 syndrome characterized, in worst cases, by severe respiratory distress, pulmonary and cardiac fibrosis, inflammatory cytokine release, immunosuppression. This condition has led to death of about 2.15% total infected world population so far. Among survivors, presence so-called persistent post-COVID-19 (PPCS) is a common finding. In PPCS presents one or more symptoms: fatigue, dyspnea, memory loss, sleep disorders, difficulty concentrating. this study, cohort 117 survivors (post-COVID-19) 144 non-infected volunteers (COVID-19-free) was analyzed using pyrosequencing defined CpG islands previously identified as suitable for biological age determination. results show consistent increase population, determining DeltaAge acceleration 10.45 ± 7.29 years (+5.25 above range normality) compared with 3.68 8.17 COVID-19-free (p < 0.0001). A significant telomere shortening parallels finding subjects Additionally, ACE2 expression decreased patients, while DPP-4 did not change. light these observations, we hypothesize that some epigenetic alterations are associated condition, particularly younger patients (< 60 years).

Language: Английский

---

Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals

BMJ Open Respiratory Research, Journal Year: 2021, Volume and Issue: 8(1), P. e001041 - e001041

Published: Nov. 1, 2021

Post-COVID-19 complications require simultaneous characterisation and management to plan policy health system responses. We describe the 12-month experience of first UK dedicated post-COVID-19 clinical service include hospitalised non-hospitalised patients.

Language: Английский

---

Post-Acute Covid-19 Syndrome

Published: May 30, 2021

The coronaviruses (CoVs) belongs to the subgroup Orthocoronavirinae in family Coronaviridae, Order Nidovirales.1 During 2002, China reports first outbreak of SARS quickly spread worldwide, leads approximately 11% fatality rate while during 2012;2 Middle East Respiratory Syndrome (MERS) originates Saudi Arabia followed by its worldwide with 37% mortality.3 December 2019, an pneumonia unknown etiology has been detected vast majority patients resides Wuhan City, Central and Hubei Province.4 Genomic research identified that this considered as coronavirus disease 2019 caused novel corona virus (CoV) labeled severe acute respiratory syndrome 2 (SARS-CoV-2), formerly called 2019-novel (2019-nCoV).5 screening management strategies are not sufficient end battled against COVID-19.6 survivors face various long terms symptoms produced COVID-19 which still matter debate.7 literature reported 50-90% individuals have persistent long-haulers but due confounders gender, age, race, duration severity infection, short term study period follow ups results hampered limited.8

Language: Английский

---

Clinical trials on the pharmacological treatment of long COVID: A systematic review

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 95(1)

Published: Nov. 9, 2022

Abstract The postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection (PASC), also known as post‐acute disease 19 (COVID‐19) or the long COVID (long COVID) is an emerging public health concern. A substantial proportion individuals may remain symptomatic months after initial recovery. An updated review published and ongoing trials focusing on managing will help identify gaps address unmet needs patients suffering from this potentially debilitating syndrome. comprehensive literature search was conducted international databases clinical trial registries inception to 31 July 2022. This included 6 54 registration records. There significant heterogeneity in characterization ascertainment primary outcomes. Most are focused individual symptoms isolated organ dysfunction, classified according cardiovascular, functional capacity, neurological psychological, fatigue, olfactory dysfunction. interventions related mechanisms causing symptoms. Although six showed improvement dysfunction studied, these studies lack internal external validity limiting generalizability. provides update pharmacological agents that could be used treat COVID. Further standardization diagnostic criteria, inclusion participants with concomitant chronic cardiometabolic diseases outcomes essential future trials.

Language: Английский

---